Posted on: August 06, 2014
The Northside Hospital Cancer Institute first in metro Atlanta to explore new treatment concept
The Northside Hospital Cancer Institute announced today its participation in a unique National Cancer Institute clinical collaboration to treat lung cancer based on a person’s genetic makeup.
The Northside Hospital Cancer Institute is the first to offer this clinical trial, referred to as Lung-MAP, in the Atlanta metro area.
Lung-MAP is a multi-drug, multi-arm, biomarker-driven clinical trial for patients with advanced squamous cell lung cancer. Organizers indicate that approximately 500 – 1,000 (10,000 enrolled) participants will be screened for more than 200 cancer-related genomic alterations per year. The results of this test will be used to assign each patient to a drug program that is best matched to their tumor’s genetic profile. Five investigational drugs from five different companies directed at specific mutations will be studied, including an immunotherapy drug, anti-PD-L1.
“We are honored to offer this clinical trial to patients in the state of Georgia and look forward to obtaining critical insights as the study progresses. This collaboration between public and private groups will provide a method of discovering new understandings and, ultimately, better care for patients in our community and across the nation,” said Dr. Rodolfo Bordoni, Georgia Cancer Specialists and primary investigator for the Lung-MAP study at The Northside Hospital Cancer Institute.
“We already have a lot of experience testing for biomarkers such as HER-2/neu to help guide treatment for breast cancer. It is exciting to now have the opportunity to apply the same model to treat lung cancer with the Lung-MAP trial,” Dr. Ronald Steis, medical oncologist with Atlanta Cancer Care and co-investigator of the Lung-MAP trial at The Northside Hospital Cancer Institute.Lung-MAP members include: the National Cancer Institute, SWOG Cancer Research, Friends of Cancer Research, the Foundation for the National Institutes of Health, five pharmaceutical companies (Amgen, Genentech, Pfizer, AstraZeneca, and AstraZeneca’s global biologics R&D arm, MedImmune), Foundation Medicine and several lung cancer advocacy organizations. The trial infrastructure is capable of testing as many as 5-7 additional drugs over the next 5 years, and will cost up to $160 million.
Read more about the Northside Hospital Cancer Institute
Read more about Lung-MAP
Filed under: Latest News & Technology,